The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1727
ISSUE 1727
April 28, 2025
Issue 1727
- Drugs for Open-Angle Glaucoma
- A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine
- In Brief: Epinephrine 1 mg Nasal Spray (neffy)
- In Brief: A New Indication for Tenecteplase (TNKase)
- Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)
- Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Drugs for Open-Angle Glaucoma
April 28, 2025 (Issue: 1727)
Glaucoma is a progressive optic neuropathy
associated with increased intraocular pressure
(IOP; normal range 8-22 mm Hg), which is the only
disease-related factor that can be modified. Topical
drugs that lower IOP are the first line of treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.